The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Primary Hyperoxaluria Treatment Market Research Report 2025
Synopsis
Primary Hyperoxaluria (PH) is a rare genetic disorder caused by deficiencies in glyoxylate metabolism leading to oxalate deposition primarily in kidneys causing end-stage renal disease. It is an inherited autosomal recessive disorder and can be of three types based on the different responsible genes: type 1 (AGXT) (PH-I), type 2 (GRHPR) (PH-II), and type 3 (HOGA1) (PH-III). Signs and symptoms may include recurrent kidney stones, hematuria, and urinary tract infections (UTIs).
The global Primary Hyperoxaluria Treatment market was valued at US$ 633 million in 2023 and is anticipated to reach US$ 918.3 million by 2030, witnessing a CAGR of 5.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Primary Hyperoxaluria Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Hyperoxaluria Treatment.
Report Scope
The Primary Hyperoxaluria Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Primary Hyperoxaluria Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Primary Hyperoxaluria Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Oxthera
Dicerna Pharmaceuticals
Allena Pharmaceuticals
Biocodex
Alnylam Pharmaceuticals
Tecoland Corporation
Zhejiang Tianxin Pharmaceutical
Takeda Pharmaceuticals
Wuxi Further Pharmaceutical
Segment by Type
Oral
Intravenous
Others
Segment by Application
Type 1
Type 2
Type 3
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Primary Hyperoxaluria Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Primary Hyperoxaluria Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Primary Hyperoxaluria (PH) is a rare genetic disorder caused by deficiencies in glyoxylate metabolism leading to oxalate deposition primarily in kidneys causing end-stage renal disease. It is an inherited autosomal recessive disorder and can be of three types based on the different responsible genes: type 1 (AGXT) (PH-I), type 2 (GRHPR) (PH-II), and type 3 (HOGA1) (PH-III). Signs and symptoms may include recurrent kidney stones, hematuria, and urinary tract infections (UTIs).
The global Primary Hyperoxaluria Treatment market was valued at US$ 633 million in 2023 and is anticipated to reach US$ 918.3 million by 2030, witnessing a CAGR of 5.5% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Primary Hyperoxaluria Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Hyperoxaluria Treatment.
Report Scope
The Primary Hyperoxaluria Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Primary Hyperoxaluria Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Primary Hyperoxaluria Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Oxthera
Dicerna Pharmaceuticals
Allena Pharmaceuticals
Biocodex
Alnylam Pharmaceuticals
Tecoland Corporation
Zhejiang Tianxin Pharmaceutical
Takeda Pharmaceuticals
Wuxi Further Pharmaceutical
Segment by Type
Oral
Intravenous
Others
Segment by Application
Type 1
Type 2
Type 3
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Primary Hyperoxaluria Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Primary Hyperoxaluria Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Primary Hyperoxaluria Treatment Market Overview
1.1 Product Overview and Scope of Primary Hyperoxaluria Treatment
1.2 Primary Hyperoxaluria Treatment Segment by Type
1.2.1 Global Primary Hyperoxaluria Treatment Market Value Comparison by Type (2024-2030)
1.2.2 Oral
1.2.3 Intravenous
1.2.4 Others
1.3 Primary Hyperoxaluria Treatment Segment by Application
1.3.1 Global Primary Hyperoxaluria Treatment Market Value by Application: (2024-2030)
1.3.2 Type 1
1.3.3 Type 2
1.3.4 Type 3
1.4 Global Primary Hyperoxaluria Treatment Market Size Estimates and Forecasts
1.4.1 Global Primary Hyperoxaluria Treatment Revenue 2019-2030
1.4.2 Global Primary Hyperoxaluria Treatment Sales 2019-2030
1.4.3 Global Primary Hyperoxaluria Treatment Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Primary Hyperoxaluria Treatment Market Competition by Manufacturers
2.1 Global Primary Hyperoxaluria Treatment Sales Market Share by Manufacturers (2019-2024)
2.2 Global Primary Hyperoxaluria Treatment Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Primary Hyperoxaluria Treatment Average Price by Manufacturers (2019-2024)
2.4 Global Primary Hyperoxaluria Treatment Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Primary Hyperoxaluria Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Primary Hyperoxaluria Treatment, Product Type & Application
2.7 Primary Hyperoxaluria Treatment Market Competitive Situation and Trends
2.7.1 Primary Hyperoxaluria Treatment Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Primary Hyperoxaluria Treatment Players Market Share by Revenue
2.7.3 Global Primary Hyperoxaluria Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Primary Hyperoxaluria Treatment Retrospective Market Scenario by Region
3.1 Global Primary Hyperoxaluria Treatment Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Primary Hyperoxaluria Treatment Global Primary Hyperoxaluria Treatment Sales by Region: 2019-2030
3.2.1 Global Primary Hyperoxaluria Treatment Sales by Region: 2019-2024
3.2.2 Global Primary Hyperoxaluria Treatment Sales by Region: 2025-2030
3.3 Global Primary Hyperoxaluria Treatment Global Primary Hyperoxaluria Treatment Revenue by Region: 2019-2030
3.3.1 Global Primary Hyperoxaluria Treatment Revenue by Region: 2019-2024
3.3.2 Global Primary Hyperoxaluria Treatment Revenue by Region: 2025-2030
3.4 North America Primary Hyperoxaluria Treatment Market Facts & Figures by Country
3.4.1 North America Primary Hyperoxaluria Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Primary Hyperoxaluria Treatment Sales by Country (2019-2030)
3.4.3 North America Primary Hyperoxaluria Treatment Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Primary Hyperoxaluria Treatment Market Facts & Figures by Country
3.5.1 Europe Primary Hyperoxaluria Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Primary Hyperoxaluria Treatment Sales by Country (2019-2030)
3.5.3 Europe Primary Hyperoxaluria Treatment Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Primary Hyperoxaluria Treatment Market Facts & Figures by Country
3.6.1 Asia Pacific Primary Hyperoxaluria Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Primary Hyperoxaluria Treatment Sales by Country (2019-2030)
3.6.3 Asia Pacific Primary Hyperoxaluria Treatment Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Primary Hyperoxaluria Treatment Market Facts & Figures by Country
3.7.1 Latin America Primary Hyperoxaluria Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Primary Hyperoxaluria Treatment Sales by Country (2019-2030)
3.7.3 Latin America Primary Hyperoxaluria Treatment Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Primary Hyperoxaluria Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Primary Hyperoxaluria Treatment Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Primary Hyperoxaluria Treatment Sales by Country (2019-2030)
3.8.3 Middle East and Africa Primary Hyperoxaluria Treatment Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Primary Hyperoxaluria Treatment Sales by Type (2019-2030)
4.1.1 Global Primary Hyperoxaluria Treatment Sales by Type (2019-2024)
4.1.2 Global Primary Hyperoxaluria Treatment Sales by Type (2025-2030)
4.1.3 Global Primary Hyperoxaluria Treatment Sales Market Share by Type (2019-2030)
4.2 Global Primary Hyperoxaluria Treatment Revenue by Type (2019-2030)
4.2.1 Global Primary Hyperoxaluria Treatment Revenue by Type (2019-2024)
4.2.2 Global Primary Hyperoxaluria Treatment Revenue by Type (2025-2030)
4.2.3 Global Primary Hyperoxaluria Treatment Revenue Market Share by Type (2019-2030)
4.3 Global Primary Hyperoxaluria Treatment Price by Type (2019-2030)
5 Segment by Application
5.1 Global Primary Hyperoxaluria Treatment Sales by Application (2019-2030)
5.1.1 Global Primary Hyperoxaluria Treatment Sales by Application (2019-2024)
5.1.2 Global Primary Hyperoxaluria Treatment Sales by Application (2025-2030)
5.1.3 Global Primary Hyperoxaluria Treatment Sales Market Share by Application (2019-2030)
5.2 Global Primary Hyperoxaluria Treatment Revenue by Application (2019-2030)
5.2.1 Global Primary Hyperoxaluria Treatment Revenue by Application (2019-2024)
5.2.2 Global Primary Hyperoxaluria Treatment Revenue by Application (2025-2030)
5.2.3 Global Primary Hyperoxaluria Treatment Revenue Market Share by Application (2019-2030)
5.3 Global Primary Hyperoxaluria Treatment Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Oxthera
6.1.1 Oxthera Corporation Information
6.1.2 Oxthera Description and Business Overview
6.1.3 Oxthera Primary Hyperoxaluria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Oxthera Primary Hyperoxaluria Treatment Product Portfolio
6.1.5 Oxthera Recent Developments/Updates
6.2 Dicerna Pharmaceuticals
6.2.1 Dicerna Pharmaceuticals Corporation Information
6.2.2 Dicerna Pharmaceuticals Description and Business Overview
6.2.3 Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Product Portfolio
6.2.5 Dicerna Pharmaceuticals Recent Developments/Updates
6.3 Allena Pharmaceuticals
6.3.1 Allena Pharmaceuticals Corporation Information
6.3.2 Allena Pharmaceuticals Description and Business Overview
6.3.3 Allena Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Allena Pharmaceuticals Primary Hyperoxaluria Treatment Product Portfolio
6.3.5 Allena Pharmaceuticals Recent Developments/Updates
6.4 Biocodex
6.4.1 Biocodex Corporation Information
6.4.2 Biocodex Description and Business Overview
6.4.3 Biocodex Primary Hyperoxaluria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biocodex Primary Hyperoxaluria Treatment Product Portfolio
6.4.5 Biocodex Recent Developments/Updates
6.5 Alnylam Pharmaceuticals
6.5.1 Alnylam Pharmaceuticals Corporation Information
6.5.2 Alnylam Pharmaceuticals Description and Business Overview
6.5.3 Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Product Portfolio
6.5.5 Alnylam Pharmaceuticals Recent Developments/Updates
6.6 Tecoland Corporation
6.6.1 Tecoland Corporation Corporation Information
6.6.2 Tecoland Corporation Description and Business Overview
6.6.3 Tecoland Corporation Primary Hyperoxaluria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Tecoland Corporation Primary Hyperoxaluria Treatment Product Portfolio
6.6.5 Tecoland Corporation Recent Developments/Updates
6.7 Zhejiang Tianxin Pharmaceutical
6.6.1 Zhejiang Tianxin Pharmaceutical Corporation Information
6.6.2 Zhejiang Tianxin Pharmaceutical Description and Business Overview
6.6.3 Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Product Portfolio
6.7.5 Zhejiang Tianxin Pharmaceutical Recent Developments/Updates
6.8 Takeda Pharmaceuticals
6.8.1 Takeda Pharmaceuticals Corporation Information
6.8.2 Takeda Pharmaceuticals Description and Business Overview
6.8.3 Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Product Portfolio
6.8.5 Takeda Pharmaceuticals Recent Developments/Updates
6.9 Wuxi Further Pharmaceutical
6.9.1 Wuxi Further Pharmaceutical Corporation Information
6.9.2 Wuxi Further Pharmaceutical Description and Business Overview
6.9.3 Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Product Portfolio
6.9.5 Wuxi Further Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Primary Hyperoxaluria Treatment Industry Chain Analysis
7.2 Primary Hyperoxaluria Treatment Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Primary Hyperoxaluria Treatment Production Mode & Process
7.4 Primary Hyperoxaluria Treatment Sales and Marketing
7.4.1 Primary Hyperoxaluria Treatment Sales Channels
7.4.2 Primary Hyperoxaluria Treatment Distributors
7.5 Primary Hyperoxaluria Treatment Customers
8 Primary Hyperoxaluria Treatment Market Dynamics
8.1 Primary Hyperoxaluria Treatment Industry Trends
8.2 Primary Hyperoxaluria Treatment Market Drivers
8.3 Primary Hyperoxaluria Treatment Market Challenges
8.4 Primary Hyperoxaluria Treatment Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Primary Hyperoxaluria Treatment Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Primary Hyperoxaluria Treatment Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Primary Hyperoxaluria Treatment Market Competitive Situation by Manufacturers in 2023
Table 4. Global Primary Hyperoxaluria Treatment Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Primary Hyperoxaluria Treatment Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Primary Hyperoxaluria Treatment Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Primary Hyperoxaluria Treatment Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Primary Hyperoxaluria Treatment Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Primary Hyperoxaluria Treatment, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Primary Hyperoxaluria Treatment, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Primary Hyperoxaluria Treatment, Product Type & Application
Table 12. Global Key Manufacturers of Primary Hyperoxaluria Treatment, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Primary Hyperoxaluria Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Hyperoxaluria Treatment as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Primary Hyperoxaluria Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Primary Hyperoxaluria Treatment Sales by Region (2019-2024) & (K Units)
Table 18. Global Primary Hyperoxaluria Treatment Sales Market Share by Region (2019-2024)
Table 19. Global Primary Hyperoxaluria Treatment Sales by Region (2025-2030) & (K Units)
Table 20. Global Primary Hyperoxaluria Treatment Sales Market Share by Region (2025-2030)
Table 21. Global Primary Hyperoxaluria Treatment Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Primary Hyperoxaluria Treatment Revenue Market Share by Region (2019-2024)
Table 23. Global Primary Hyperoxaluria Treatment Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Primary Hyperoxaluria Treatment Revenue Market Share by Region (2025-2030)
Table 25. North America Primary Hyperoxaluria Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Primary Hyperoxaluria Treatment Sales by Country (2019-2024) & (K Units)
Table 27. North America Primary Hyperoxaluria Treatment Sales by Country (2025-2030) & (K Units)
Table 28. North America Primary Hyperoxaluria Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Primary Hyperoxaluria Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Primary Hyperoxaluria Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Primary Hyperoxaluria Treatment Sales by Country (2019-2024) & (K Units)
Table 32. Europe Primary Hyperoxaluria Treatment Sales by Country (2025-2030) & (K Units)
Table 33. Europe Primary Hyperoxaluria Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Primary Hyperoxaluria Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Primary Hyperoxaluria Treatment Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Primary Hyperoxaluria Treatment Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Primary Hyperoxaluria Treatment Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Primary Hyperoxaluria Treatment Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Primary Hyperoxaluria Treatment Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Primary Hyperoxaluria Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Primary Hyperoxaluria Treatment Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Primary Hyperoxaluria Treatment Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Primary Hyperoxaluria Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Primary Hyperoxaluria Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Primary Hyperoxaluria Treatment Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Primary Hyperoxaluria Treatment Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Primary Hyperoxaluria Treatment Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Primary Hyperoxaluria Treatment Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Primary Hyperoxaluria Treatment Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Primary Hyperoxaluria Treatment Sales (K Units) by Type (2019-2024)
Table 51. Global Primary Hyperoxaluria Treatment Sales (K Units) by Type (2025-2030)
Table 52. Global Primary Hyperoxaluria Treatment Sales Market Share by Type (2019-2024)
Table 53. Global Primary Hyperoxaluria Treatment Sales Market Share by Type (2025-2030)
Table 54. Global Primary Hyperoxaluria Treatment Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Primary Hyperoxaluria Treatment Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Primary Hyperoxaluria Treatment Revenue Market Share by Type (2019-2024)
Table 57. Global Primary Hyperoxaluria Treatment Revenue Market Share by Type (2025-2030)
Table 58. Global Primary Hyperoxaluria Treatment Price (US$/Unit) by Type (2019-2024)
Table 59. Global Primary Hyperoxaluria Treatment Price (US$/Unit) by Type (2025-2030)
Table 60. Global Primary Hyperoxaluria Treatment Sales (K Units) by Application (2019-2024)
Table 61. Global Primary Hyperoxaluria Treatment Sales (K Units) by Application (2025-2030)
Table 62. Global Primary Hyperoxaluria Treatment Sales Market Share by Application (2019-2024)
Table 63. Global Primary Hyperoxaluria Treatment Sales Market Share by Application (2025-2030)
Table 64. Global Primary Hyperoxaluria Treatment Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Primary Hyperoxaluria Treatment Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Primary Hyperoxaluria Treatment Revenue Market Share by Application (2019-2024)
Table 67. Global Primary Hyperoxaluria Treatment Revenue Market Share by Application (2025-2030)
Table 68. Global Primary Hyperoxaluria Treatment Price (US$/Unit) by Application (2019-2024)
Table 69. Global Primary Hyperoxaluria Treatment Price (US$/Unit) by Application (2025-2030)
Table 70. Oxthera Corporation Information
Table 71. Oxthera Description and Business Overview
Table 72. Oxthera Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Oxthera Primary Hyperoxaluria Treatment Product
Table 74. Oxthera Recent Developments/Updates
Table 75. Dicerna Pharmaceuticals Corporation Information
Table 76. Dicerna Pharmaceuticals Description and Business Overview
Table 77. Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Product
Table 79. Dicerna Pharmaceuticals Recent Developments/Updates
Table 80. Allena Pharmaceuticals Corporation Information
Table 81. Allena Pharmaceuticals Description and Business Overview
Table 82. Allena Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Allena Pharmaceuticals Primary Hyperoxaluria Treatment Product
Table 84. Allena Pharmaceuticals Recent Developments/Updates
Table 85. Biocodex Corporation Information
Table 86. Biocodex Description and Business Overview
Table 87. Biocodex Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Biocodex Primary Hyperoxaluria Treatment Product
Table 89. Biocodex Recent Developments/Updates
Table 90. Alnylam Pharmaceuticals Corporation Information
Table 91. Alnylam Pharmaceuticals Description and Business Overview
Table 92. Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Product
Table 94. Alnylam Pharmaceuticals Recent Developments/Updates
Table 95. Tecoland Corporation Corporation Information
Table 96. Tecoland Corporation Description and Business Overview
Table 97. Tecoland Corporation Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Tecoland Corporation Primary Hyperoxaluria Treatment Product
Table 99. Tecoland Corporation Recent Developments/Updates
Table 100. Zhejiang Tianxin Pharmaceutical Corporation Information
Table 101. Zhejiang Tianxin Pharmaceutical Description and Business Overview
Table 102. Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Product
Table 104. Zhejiang Tianxin Pharmaceutical Recent Developments/Updates
Table 105. Takeda Pharmaceuticals Corporation Information
Table 106. Takeda Pharmaceuticals Description and Business Overview
Table 107. Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Product
Table 109. Takeda Pharmaceuticals Recent Developments/Updates
Table 110. Wuxi Further Pharmaceutical Corporation Information
Table 111. Wuxi Further Pharmaceutical Description and Business Overview
Table 112. Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Product
Table 114. Wuxi Further Pharmaceutical Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Primary Hyperoxaluria Treatment Distributors List
Table 118. Primary Hyperoxaluria Treatment Customers List
Table 119. Primary Hyperoxaluria Treatment Market Trends
Table 120. Primary Hyperoxaluria Treatment Market Drivers
Table 121. Primary Hyperoxaluria Treatment Market Challenges
Table 122. Primary Hyperoxaluria Treatment Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Primary Hyperoxaluria Treatment
Figure 2. Global Primary Hyperoxaluria Treatment Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Primary Hyperoxaluria Treatment Market Share by Type in 2023 & 2030
Figure 4. Oral Product Picture
Figure 5. Intravenous Product Picture
Figure 6. Others Product Picture
Figure 7. Global Primary Hyperoxaluria Treatment Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Primary Hyperoxaluria Treatment Market Share by Application in 2023 & 2030
Figure 9. Type 1
Figure 10. Type 2
Figure 11. Type 3
Figure 12. Global Primary Hyperoxaluria Treatment Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Primary Hyperoxaluria Treatment Market Size (2019-2030) & (US$ Million)
Figure 14. Global Primary Hyperoxaluria Treatment Sales (2019-2030) & (K Units)
Figure 15. Global Primary Hyperoxaluria Treatment Average Price (US$/Unit) & (2019-2030)
Figure 16. Primary Hyperoxaluria Treatment Report Years Considered
Figure 17. Primary Hyperoxaluria Treatment Sales Share by Manufacturers in 2023
Figure 18. Global Primary Hyperoxaluria Treatment Revenue Share by Manufacturers in 2023
Figure 19. The Global 5 and 10 Largest Primary Hyperoxaluria Treatment Players: Market Share by Revenue in 2023
Figure 20. Primary Hyperoxaluria Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 21. Global Primary Hyperoxaluria Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 22. North America Primary Hyperoxaluria Treatment Sales Market Share by Country (2019-2030)
Figure 23. North America Primary Hyperoxaluria Treatment Revenue Market Share by Country (2019-2030)
Figure 24. U.S. Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 25. Canada Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Europe Primary Hyperoxaluria Treatment Sales Market Share by Country (2019-2030)
Figure 27. Europe Primary Hyperoxaluria Treatment Revenue Market Share by Country (2019-2030)
Figure 28. Germany Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. France Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. U.K. Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Italy Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Russia Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Primary Hyperoxaluria Treatment Sales Market Share by Region (2019-2030)
Figure 34. Asia Pacific Primary Hyperoxaluria Treatment Revenue Market Share by Region (2019-2030)
Figure 35. China Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Japan Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. South Korea Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. India Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Taiwan Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Indonesia Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Thailand Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Malaysia Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Philippines Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Primary Hyperoxaluria Treatment Sales Market Share by Country (2019-2030)
Figure 46. Latin America Primary Hyperoxaluria Treatment Revenue Market Share by Country (2019-2030)
Figure 47. Mexico Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Brazil Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Argentina Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Primary Hyperoxaluria Treatment Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Primary Hyperoxaluria Treatment Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. U.A.E Primary Hyperoxaluria Treatment Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Primary Hyperoxaluria Treatment by Type (2019-2030)
Figure 56. Global Revenue Market Share of Primary Hyperoxaluria Treatment by Type (2019-2030)
Figure 57. Global Primary Hyperoxaluria Treatment Price (US$/Unit) by Type (2019-2030)
Figure 58. Global Sales Market Share of Primary Hyperoxaluria Treatment by Application (2019-2030)
Figure 59. Global Revenue Market Share of Primary Hyperoxaluria Treatment by Application (2019-2030)
Figure 60. Global Primary Hyperoxaluria Treatment Price (US$/Unit) by Application (2019-2030)
Figure 61. Primary Hyperoxaluria Treatment Value Chain
Figure 62. Primary Hyperoxaluria Treatment Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
